| Drug Name |
Dorzolamide hydrochloride |
| Drug ID |
BADD_D00713 |
| Description |
Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380] |
| Indications and Usage |
Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.[L11377] It can also be used in combination with [timolol] for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.[L11380]
Its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.[A190183] |
| Marketing Status |
approved |
| ATC Code |
S01EC03 |
| DrugBank ID |
DB00869
|
| KEGG ID |
D00653
|
| MeSH ID |
C062765
|
| PubChem ID |
6918132
|
| TTD Drug ID |
D05UYW
|
| NDC Product Code |
14445-006; 42571-141; 61314-019; 52133-0031; 72266-197; 62332-519; 55545-0703; 0006-3519; 60429-114; 69315-304; 58032-0142; 65977-0031; 50090-4882; 50383-232; 53104-7584; 65089-0039; 68083-489; 58032-1024; 73377-182 |
| UNII |
QZO5366EW7
|
| Synonyms |
dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152 |
